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Background. COPD is a common worldwide condition associated with morbidity and mortality. Its symptoms can be easily 
overlooked, accounting for an elevated level of under-recognition and under-diagnosis. Knowledge of the prevalence of COPD and the 
significance of its associated factors in the population enables better management of medical resources.
Objectives. To establish the prevalence of COPD in General Practice patients in the Central Region of Portugal and analyze the correla-
tion with associated factors. 
Methods. Cross-sectional study of patients’ data with COPD (R95, International Classification for Primary Care 2), anonymously gath-
ered from the official database of the Central Health Administration of Portugal.
Results. Out of 937,817 individuals, 24,148 patients were identified with COPD, a prevalence of 2.57/100,000. 73.7% were above 65 
years of age, and 60.2% were males. BMI was recorded in 60.2% patients, FEV1(%) in 8.0%, and smoking pack-years in 37.1%. Age and 
BMI were significantly negatively correlated (ρ = -0.032, p < 0.001), with the same occurring between age and FEV1(%) (ρ = -0.073, p < 
0.05). A strong association of COPD with male gender and older age groups was found.
Conclusions. The prevalence of COPD was significantly higher in males, and age was identified as a risk factor for this condition. Higher 
age was non-significantly associated with lower FEV1(%) and significantly associated with BMI. The lack of e-records calls for an im-
provement.
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Background
chronic obstructive Pulmonary Disease (COPD) is an ob-
structive pulmonary pathology characterized by a not fully re-
versible and progressive limitation of the airflow.
this pathology is described as a global health problem, with 
an elevated level of significance conferred by its high mortality 
and morbidity, as it is currently listed as the fourth leading cause 
of death worldwide [1, 2]. By the end of 2020, COPD is projected 
to be the third leading cause of death worldwide, with the dis-
ease burden constantly increasing over the next decades due 
to aging of the population, as well as continuous exposure to 
COPD-related risk factors [3, 4]. 
The genesis of this chronic disease is the persistent inflam-
matory response of the airspaces, responsible for the irrevers-
ible alteration of its proprieties, leading to remodeling and 
consequent deformation, causing a progressive decline of the 
patient’s pulmonary function [5, 6]. 
The typical findings in this pathology are a persistent de-
crease of the percentage of forced expiratory volume in the first 
second FEV1(%) during spirometry, accompanied by respiratory 
symptoms, usually in the form of a persistent cough with spu-
tum (chronic phlegm) [7, 8]. 
In Portugal, the prevalence of this condition is estimated 
to be 9 to 14% [9], concomitant with an elevated level of the 
under-diagnosed population (86.2%) [10], while worldwide, the 
prevalence of COPD was estimated at 11.7% in 2010 [11]. 
Smoking is a leading risk factor associated with COPD. Smok-
ers have a higher prevalence of respiratory symptoms, higher 
annual decline in FEV1(%) and higher mortality associated with 
the disease when compared to non-smokers [12]. Other causes 
like bad breathing atmosphere and chronic dust exposure can 
be added [8–13].
aging is also widely referred to as a risk factor for coPd, 
but whether this is due to aging of the airways and parenchyma 
itself or due to the cumulative effects of exposures throughout 
life still remains controversial [13]. 
Gender differences have also been described in COPD, with 
past studies showing a higher prevalence amongst males; how-
ever, more recent studies have shown a tendency toward a nor-
malization of the prevalence among both genders. This phe-
nomenon is largely attributed to the change in tobacco smoking 
patterns, with an increase of tobacco smoking among females 
throughout the years [14]. The clinical presentation of COPD can 
also vary according to gender, with females being less likely than 
males to report dyspnea as the main symptom [15, 16]. COPD is 
listed as the most probable diagnosis more often in males than 
in females, and thus it is associated with a greater level of un-
der-diagnosis among females, indicating the great importance 
of spirometry in the diagnosis of this condition [17]. Females 
have also been described as more susceptible to smoke expo-
sure, showing a greater pulmonary function decline associated 
with lower smoking exposure when compared to males [18]. 



























Lung function specific measurements, such as FEV1(%), are 
widely used as predictors of mortality in coPd, as well as in the 
general population [19–22]. However, other factors have been 
described as good predictors in the mortality associated with this 
condition [23], with prognostic tools such as the BODE index mea-
suring the patient’s BMI, degree of airflow obstruction, dyspnea 
and exercise capacity, showing better results in predicting the risk 
of death in COPD patients than using FEV1(%) alone [24, 25]. 
There are estimations of the prevalence of COPD in the Por-
tuguese population based on an analysis of clusters [10]. Portu-
guese General Practitioners in Central Portugal work daily with 
an informatics program for e-health records to classify diseases, 
namely COPD using the ICPC2, so making it possible to deter-
mine COPD's prevalence.
Objectives 
1. To establish the prevalence of “Chronic Obstructive Pul-
monary Disease (R95)” in the area of the Re gional Health 
Administration of Central Portugal. 
2. To characterize socio-demographics of COPD patients such 
as: age, gender, FEV1(%), BMI and smoking burden. 
Material and methods 
This was a cross-sectional study of data gathered on Decem-
ber 31st of 2018. The study was approved by the ethics commit-
tee of the Regional Health Administration of Central Portugal. 
data was granted by the it department of the regional Health 
Administration of Central Portugal. 
Data referring to age, gender, smoking burden, FEV1(%) and 
BMI from patients 40 years of age or more classified with the 
ICPC-2 of “Chronic Obstructive Pulmonary Disease (R95)” was 
collected anonymously. 
All statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS), version 25. Descriptive 
statistics included mean and standard deviation for continuous 
variables and absolute and relative frequency for categorical 
variables. Distribution normality was assessed using the Kol-
mogorov–Smirnov test. Chi-square and Mann–Whitney tests 
were used to establish associations and differences between 
variables, respectively. For correlation of variables, we used 
Spearman’s correlation coefficient and Partial Correlations to 
adjust for gender. Correlations were considered very strong 
when a coefficient was greater than 0.90, strong if between 0.70 
and 0.90, moderate if between 0.50 and 0.70, weak if between 
0.30 and 0.50 and very weak if less than 0.30. The results were 
significant at p < 0.05.
Results 
Out of of 937,817 individuals, 24,148 patients were classi-
fied as ICPC-2 “Chronic Obstructive Pulmonary Disease (R95)” 
and were included in this study. The prevalence of COPD was 
2.57/100,000. The characteristics of the participants are shown 
in Table 1. Regarding gender, 60.2% (14,544) were male, and 
39.8% (9,604) were female. The mean age was 71.9 ± 11.6 
years, and the majority were above 65 years of age (73.7%; n = 
17,805). The Baixo Mondego region was the most represented 
in our sample (20.1%; n = 4,853). Out of the 24,148 patients, 
only 15,470 had BMI records, 1,921 had FEV1(%), and 8,957 had 
pack-years registered. Mean BMI was 28.6 ± 7.1 kg/m2, mean 
FEV1(%) was 62.8 ± 29.8 and mean pack-years was 10.3 ± 22.0.
Table 2 represents the gender comparison of the collected 
data. Females with COPD were significantly older (73.5 years 
old) compared to males (70.9 years old; p < 0.001), and the lat-
ter was significantly overrepresented in the age group below 65 
years of age (28.2%; p < 0.001). Gender was associated with the 
participant’s region (p < 0.001). Female patients with COPD had 
a higher median BMI (M = 29.3; p < 0.001) and FEV1(%) (M = 
66.1; p = 0.001) but lower median pack-years (M = 3.4 ± 11.5) 
compared to males. 
Table 1. Sample characteristics







Age (years), mean ± SD 24,148 71.9 ± 11.6


























BMI (kg/m2), mean ± SD 15470 28.6 ± 7.1
FEV1(%) predicted, mean 
± SD 1921 62.8 ± 29.8
Pack-years, mean ± SD 8957 10.3 ± 22.0
BMI – Body Mass Index, FEV1(%) – Forced Expiratory Volume in the first 
second, n – number of patients with available data, SD – standard de-
viation.







Age (years), mean ± SD 70.9 ± 11.2 73.5 ± 11.9 < 0.001





































BMI (kg/m2),  
mean ± SD 28.1 ± 6.0 29.3 ± 8.5 < 0.001
FEV1(%) predicted, 
mean ± SD 61.1 ± 27.9 66.1 ± 33.2 0.001
Pack-years, mean ± SD 14.9 ± 25.8 3.4 ± 11.5 < 0.001
MI – Body Mass Index, FEV1(%) – Forced Expiratory Volume in the first 
second, SD – standard deviation.
mean age and Bmi were highest in the Pinhal interior sul 
region and lowest in Baixo Vouga. Mean FEV1(%) was higher 
in the interior regions of cova da Beira and Pinhal interior do 
Sul and lower in the seaside locations (Pinhal Litoral and Baixo 
Mondego). Mean pack-years were higher in Baixo Mondego and 
Cova da Beira but lower in Pinhal Interior Sul and Dão Lafões. 



























There were significant differences in terms of age (p < 0.001), 
BMI (p < 0.001), FEV1(%) (p < 0.001) and pack-years (p < 0.001) 
between regions.
Unadjusted and adjusted correlations between continuous 
variables using Spearman’s correlation coefficient are shown in 
Table 3. There were negative correlations between age, BMI and 
FEV1(%). Age and pack-years showed a positive correlation. Par-
tial correlations controlling for gender showed a negative cor-
relation between age and FEV1(%) (rS = -0.065) and positive cor-
relations between age and pack-years (rS = 0.223) and between 
pack-years and BMI (rS = 0.058). All significant correlations were 
deemed as very weak (coefficient < 0.3).
Table 3. Spearman’s correlation matrix of clinical variables
Variables (unadjusted) Age BMI FEV1
BMI (kg/m2) -0.032**
FEV1(%) -0.073* 0.034
Pack-years (greater than 0) 0.219** 0.005 -0.051
Variables (adjusted for gender) Age BMI FEV1
BMI (kg/m2) 0.046
FEV1(%) -0.065* 0.052
Pack-years (greater than 0) 0.223** 0.058* -0.010
Discussion 
We identified 24,148 patients that were classified with 
ICPC-2 “Chronic Obstructive Pulmonary Disease (R95)” out of 
937,817 individuals, resulting in a prevalence of COPD of 2.57 
per 100,000. The calculated prevalence of COPD in the Central 
Region of Portugal was significantly lower than the prevalence 
estimated for this disease in past studies, both worldwide and 
in Portugal [9, 10, 26–29]. There are many aspects that can con-
tribute to such a low prevalence in this study: the methodol-
ogy used in most observational studies being different from the 
clinical one we used, which is based on existing records. The au-
thors cannot confirm the realization of spirometry with set cri-
teria for COPD diagnosis in every patient, even though the low 
prevalence may reflect the lack of availability of spirometry in 
this setting. This study was based on records of chronic patients’ 
problems and a documented diagnosis of coPd for the calcula-
tion of the prevalence of COPD [10]. The low prevalence can be 
explained by lack of clinical findings, lack of ease of spirometry 
or even due to the lack of a doctor’s interest concerning this 
important health topic [29].
Age was identified as a risk factor for this condition, with the 
age group above 65 years of age being the most represented in 
our population. A higher age was also associated with greater 
pulmonary function decline (lower FEV1(%)) and lower BMI, 
both being criteria for a worse prognosis [19–25]. Smoking bur-
den was also found to increase with age.
Airway obstruction for this disease was found to be more se-
vere (with lower FEV1(%)) amongst patients in seaside locations. 
The prevalence was significantly higher in males, with a con-
comitant higher smoking burden in this gender. It is safe to as-
sume that even though recent studies have shown a tendency 
toward normalization of the prevalence amongst genders [13], 
in the central region of Portugal, the prevalence of coPd was 
higher in males, probably due to a lack of change in smoking 
patterns, with smoking still being highly associated with the 
male gender in this area. 
all the data was gathered thanks to the existence of a Pri-
mary Health Care national health database, containing infor-
mation about people assisted with acute and chronic problems 
classified according to ICPC2 in the e-records made by doctors 
of General Practice/Family Medicine using the comprehensive 
e-platform. Despite this, there was a considerable lack of reg-
istrations regarding FEV1(%), BMI and smoking burden in the 
form of pack-years for the patients classified with COPD. For 
FEV1(%) registrations, the collected data was related to spirom-
etry results in the study year. Lack of knowledge of spirometry 
does not mean it has not been made some years ago. FEV1(%) is 
a highly reproductive measurement, strongly related to mortal-
ity [22, 30], and its registration in the clinical records of patients 
with COPD is highly recommended.
Limitations of the study
Although the ICPC-2 criteria for the classification of COPD 
[31] define the need for “objective evidence of airway obstruc-
tion, not/only partially relieved by bronchodilators”, we cannot 
guarantee that all doctors, when classifying with ICPC-2 R95, had 
access to the results of spirometry according to the guidelines of 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
[32]. We recognize that probably not all patients who actually suf-
fer from coPd are in this database for medical underdiagnosis, 
and since this is a study based on recording consultation data, 
we have no way of ensuring that all doctors followed the criteria 
expressed when classifying with the R95. Most complete diagno-
ses should take in consideration the pathophysiology that leads 
to chronic airway obstruction [33–35].
Strengths
this a large volume data study, encompassing a whole health 
region in Portugal.
Opportunities
To change for better the diagnosis of COPD and to have bet-
ter epidemiologic data on this medical issue.
Conclusions 
coPd is a pathology mostly associated with the male gen-
der and with older age groups in the Central Region of Portugal. 
smoking burden was also higher amongst males when com-
pared to females in this region. 
the calculated prevalence of coPd was considerably low in 
Central Portugal Primary Care databases. There is a need to im-
prove classification, quantitatively and qualitatively, by doctors 
in Primary Health care, especially for associated factors such as 
FEV1(%), BMI and smoking burden.
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